Gilead agrees not to raise prices on HIV medicines for state AIDS drug programs

Taking stock of the drug industry, from the lab to the medicine chest

October 21, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Justin Sullivan/Getty Images STAT+ | Gilead agrees not to raise prices on HIV medicines for state AIDS drug programs ADAPs provided recent utilization data to Gilead so the company could better understand how price hikes would financially strain the programs By Ed Silverman STAT+ | Effort to guide treatment of cancer with novel blood tests may get boost from new research New data from Europe suggest Natera's Signatera ctDNA blood test can reveal which cancer patients need more therapy and who may already be cured. By Andrew Joseph STAT+ | Kaiser Permanente, DOJ nearing resolution in $1 billion Medicare fraud case The DOJ says that Kaiser systematically altered patients' medical records to make them appear sicker and boost its revenue. By Tara Bannow Photo by Jeff Pinette YouTuber 'Doctor Mike' thinks medicine needs a better social media strategy Trust in public health institutions has been declining for years. This physician has some ideas to fix that By Alex Hogan

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser